Topic Listing for Incyte

Ability Develop Commercialize Dfc Adversely Affected Dispute Arose Ability Develop Commercialize Reverset Adversely Affected Dispute Arose
Ability Discover Develop Formulate Manufacture Commercialize Drug Candidate Ability Generate Revenues Diminished Unable Obtain Acceptable Prices
Ability Obtain Patent Protection Freedom Operate Discoveries Continue Absence Established Market Common Stock Fair Value Thereof
Acceleration Maturity Rescission Annulment Accounting Certain Investments Debt Equity Securities
Accounting Certain Investments Held Not-for-profit Organizations Accounting Costs Associated Exit Disposal Activities
Accounting Costs Computer Software Developed Obtained Internal Accounting Costs Computer Software Sold Leased Otherwise Marketed
Accounting Derivative Financial Instruments Hedging Activities Accounting Derivative Instruments Hedging Activities
Accounting Impairment Disposal Long Lived Assets Accounting Long-term Investments
Accounting Research Development Costs Accounting Stock Issued Employees
Accounting Stock-based Compensation Accounts Receivable
Accumulated Other Comprehensive Income Loss Acquisition Competing Product
Acquisition Maxia Acquisition Transaction
Acts Holders Additional Documents Incorporated Reference
Adjustment Conversion Rate Make-whole Fundamental Changes Adjustment Conversion Rate Shall Adjusted Time Follows
Adjustment Shares Administration
Advance Notice Provisions Advertising Costs
Affiliate After Effective Date
Agreement Agreement Matters Related Transaction Shall Governed Construed Accordance
Agreements Other Named Executive Officers Alliance Pfizer
Although Obtained Special Protocol Assessment Jak Inhibitor Myelofibrosis Amendment
Amendment 1991 Stock Plan Was Approved Amendment 1993 Directors Stock Option Plan
Amendment 1993 Directors Stock Option Plan Was Approved Amendment 1997 Employee Stock Purchase Plan
Amendment 1997 Employee Stock Purchase Plan Was Approved Amendment Articles Incorporation Bylaws Change
Amendment Purchase Agreement Amendment Termination
Amendments Amendments Articles Incorporation Bylaws Change
Amount Animal Product
Animal Products Announces 2004 Financial Results Provides 2005 Guidance
Announces 2007 Financial Results Provides 2008 Guidance Announces Financial Results
Annual Incentive Compensation Plan Annual Meeting 2006
Annual Meeting 2008 Annual Report
Anti-stack Amount Anti-stacking
Anything 304 Contrary Notwithstanding Agreement Hold Sums Trust Application Certain Investments
Application Money Collected Assays
Assignment Attachment
Attachment C-1 Attorneys-in-fact
Audit Committee Audited Financial Statements Year-ended 2004 Included Annual Report
Authorized Disclosure Available Information
Background Incytes Transition Small-molecule Drug Discovery Development Bankruptcy
Barry Ariko Base Salary
Basis Presentation Because Activities Involve Hazardous Materials Subject Claims Relating
Beneficial Owner Beneficial Ownership Reporting Compliance
Beta-hsd1 Inhibitor Diabetes Beta-hsd1 Inhibitor Program
Binding Effect Board Committees
Board Directors Board Directors Executive Compensation
Board Directors Recommends Vote Amendment 1991 Stock Plan Board Directors Recommends Vote Amendment 1993 Stock Option
Board Directors Recommends Vote Amendment 1997 Employee Stock Board Directors Stockholders Incyte Corporation
Board Meetings Board Meetings Committees
Book-entry Provisions Bout Incyte
Brian Metcalf Business
Business Combinations Business Loss Thereof Not Disadvantageous Material Respect Securityholders
C-met Solid Tumors Cancellation
Cancer Portfolio Capital Stock
Case Clauses Conflicts Breaches Defaults Violations Liens Either Case Time Following Shall Occur
Cash Cash Compensation
Cash Equivalents Cash Flows Investing Activities
Cash Flows Operating Activities Cash Payments Lieu Fractional Shares
Cash Position Ccr2 Antagonism
Ccr2 Antagonist Ccr2 Antagonist Program
Ccr2 Antagonist Program Inflammation Ccr2 Inhibitor Program
Ccr2 Receptor Antagonist Program Ccr2 Receptor Antagonist Program Inflammatory Diseases
Ccr5 Antagonist Ccr5 Antagonist Program
Ccr5 Antagonist Program Hiv Ccr5 Inhibitor Program
Certain Federal Income Tax Consequences Awards 1991 Stock Certain Federal Income Tax Consequences Options Directors Option
Certain Federal Income Tax Consequences Participating Employee Stock Certain Relationships Related Transactions
Certain Relationships Related Transactions Director Independence Certain Transactions
Certification Change Composition Board Directors Result Fewer One-half Incumbent
Change Control Change Control Shall Mean Occurrence Either Following Events
Change Vote Revoke Proxy Changes Internal Control Over Financial Reporting
Chief Executive Officer Compensation Claims
Clinical Pipeline Code Shall Mean Internal Revenue 1986 Amended
Collaborations Licensing Agreements Collaborative License Agreement
Collaborative License Agreement Pharmasset Inc Collaborative Research License Agreement
Collaborative Research License Agreement Pfizer Collateral Security
Collection Indebtedness Suits Enforcement Trustee Combination Product
Comfort-i Trial Comfort-ii Trial
Commencement Commercial Strategy
Commercially Reasonable Efforts Commitments
Committee Chair Common Stock
Common Stock Offering Communications Board Directors
Compensation Committee Compensation Committee Interlocks Insider Participation
Compensation Committee Report Compensation Directors
Compensation Indemnity Compensation Philosophy Objectives
Competition Competition Develop Commercialize Similar Drug Products
Compliance Certificate Compliance Trust Indenture Act
Compound Computation Ratios Earnings Fixed Charges
Concentration Credit Risk Concentrations Credit Risk
Condensed Consolidated Balance Sheet Data Condensed Consolidated Statements Comprehensive Loss
Conditions Indemnification Conduct Research
Conference Call Information Conference Call Webcast Scheduled 430 Today
Conference Call Webcast Scheduled 830 Today Conflicts Arise Between Collaborators Including Pfizer Licensees Advisors
Conflicts Arise Between Collaborators Including Pharmasset Pfizer Licensees Conflicts Arise Between Collaborators Licensees Advisors Act Self-interest
Consent Holders Consent Independent Registered Public Accounting Firm
Consent Optionee Impair Such Optionees Rights Increase His Consolidate Etc Only Certain Terms
Consolidation Merger Sale Conveyance Lease Construction
Consummation Transactions Contemplated Agreement License Seeking Impose Limitations Contingencies
Control Control Holders
Controls Procedures Conversion Notice
Conversion Procedures Conversion Securities
Conversion Shares Series Preferred Stock Convertible Debt Derivative Accounting
Convertible Subordinated Notes Convey Transfer Assign Mortgage Pledge Trustee Security Securities
Cooperate Assist Filings Required National Association Securities Dealers Corporate Governance Guidelines
Costs Counterparts
Courts Creation Direct Financial Obligation Off-balance Sheet Arrangement
Creation Direct Financial Obligation Off-balance Sheet Arrangement Registrant Critical Accounting Policies Significant Estimates
Cross Over Placebo Incb18424 Cumulative Voting Permitted Election Directors
Cusip Isin Numbers D-1
D-2 D-3
Date Date 2006
Date After His Her Death Date After Termination Optionees Service Occurs Because His
Date Report 2006 Earliest Event Reported Incyte Corporation David Hastings
Debt Deferred
Defined Contribution Plan Definitions
Delay Omission Not Waiver Deliver Part Sales Proceeds Payment Exercise Price Withholding
Delivery Collateral Departure Directors Certain Officers Election Appointment Compensatory
Departure Directors Principal Officers Election Appointment Depend Collaboration Pfizer Development Commercialization Ccr2 Antagonist Compounds
Depend Heavily Success Most Advanced Product Candidates Might Depend Key Employees Competitive Market Skilled Personnel Loss
Dependent Relative Known Then Such Other Person Designate Deposit Escrow Account Investments
Derivative Financial Instruments Description Amendment
Designated Event Repurchase Notice Designation Beneficiary
Determining Whether Nonmonetary Transaction Involves Receipt Productive Assets Development Committee
Development Committee Meeting Development Information Exchange
Development Plan Development Reports
Diabetes Diabetes Opportunity
Diligence Director Independence
Director Nomination Director Nominations
Directors Directors Certain Officers Election Appointment Compensatory Arrangements
Directors Executive Officers Corporate Governance Directors Executive Officers Registrant
Directors Stock Option Plan Discharge Indenture
Discharge Liability Securities Disclosures Segments Enterprise Related Information
Discontinuation Proteome Subsidiary Operation Sale Assets Discontinuation Withdrawal
Discovery Discovery Programs
Disputes Distributions Escrow Account
Documents Filed Part Report Documents Incorporated Reference
Drug Discovery Development Operations Conducted Headquarters Wilmington Delaware Drug Discovery Programs
Duration Amendments Duration Trial
Duties Trustee Early Stage Drug Discovery Development Efforts Unsuccessful
Early-stage Discovery Programs Effect Certain Corporate Events
Effect Supplemental Indentures Effect Termination
Effective Date Effective Date Shall Mean 2006
Effective Term Patents Decreased Due Changes United States Effectiveness Period
Effects Against Hiv Mutations Efforts Discover Develop Potential Drug Candidates Not Lead
Electronic Copies Request Amended Supplemented Prospectus Complying Act Eli Lilly
Eligibility Eligibility Disqualification
Eligibility Price Shares Employee
Employee Been Employed Given Enrollment Date Shall Eligible Employee Stock Purchase Plan
Employee Stock Purchase Plan Amendment Employment Contracts Termination Change-in-control Arrangements
Employment Rights Encounter Difficulties Integrating Companies Acquire Harm Operations Financial
Encourage Take Advantage Internet Telephone Voting Available End Option Values
Enlargement Number Board Directors Increased Time Vote Majority Entire Agreement Amendment
Entitled Vote Entry Material Definitive Agreement
Equity Compensation Equity Compensation Plan Information
Equity Grant Practices Equity-based Incentive Awards
Establishment Escrow Account Establishment Purpose
Estimates Evaluation Disclosure Controls Procedures
Even Obtainable Quorum Disinterested Directors Directs Independent Legal Event Default
Events Default Evidence Provide Acceptance Appointment Hereunder Successor Trustee Respect
Exact Name Registrant Specified Charter Example
Exceed Percent Participants Aggregate Compensation Such Offering Period Except Per Share Data
Excess Escrow Funds Exchange Act
Exchange Act Shall Mean Securities 1934 Amended Exclusion Damages
Execution Execution Authentication
Execution Record Amendment Restatement Plan Board Effective Date Executive Compensation
Executive Employment Change Control Agreements Executive Officers Registrant
Exercise Price Exhibits
Existence Expect Incur Losses Future Not Achieve Maintain Profitability
Expectations Regarding Competition Experimental Station Route 141 Henry Clay Road
Experimental Station Route 141 Henry Clay Road Building Expiration Date Determined Pursuant Subsection Above
Extent Such Damages Accrue Prior End Effectiveness Period Face Significant Competition Drug Discovery Development Efforts Not
Fail Enter Additional In-licensing Agreements Arrangements Unsuccessful Business Fail Enter Additional Licensing Agreements Arrangements Unsuccessful Business
Fail Manage Growth Effectively Ability Develop Commercialize Products Failed Perform Obligations Set Forth Within Time Period
Fair Market Value Fair Market Value Shall Mean Date Common Stock
Fair Market Value Shall Mean Price Stock Determined Fair Value Measurements
Fda Fdca
Fees Expenses Escrow Agent Filing Prosecution Maintenance
Finance Committee Financial Guidance
Financial Guidance Update Financial Overview Results
Financial Results Financial Statements Exhibits
Financing Costs Related Long-term Debt Following Provisions Shall Apply Only Global Securities
Force Majeure Foregoing Provisions Applicable Then Fair Market Value Shall
Foreign Currency Translation Foreign Exchange
Form 10-k Form 10-q
Form Dating Form Security
Form Specified Location Person Designated Receipt Thereof Form Transfer Certificate
Former Name Address Changed Since Last Report Forward Looking Statements
Forward-looking Statements Forward-looking Statements Reflect Current Views Respect Future Events
Fte Full Retirement
Further Further Actions
Further Assurances Further Instruments Acts
Future Milestone Royalty Payments Gene Genomics-related Intellectual Property Gain Loss Certain Derivative Financial Instruments
Gain Loss Certain Derivative Financial Instruments Net Gain Loss Redemption Repurchase Convertible Subordinated Notes
Gain Loss Repurchase Convertible Subordinated Notes Gain Repurchase Convertible Subordinated Notes
General Provisions General Representations Warranties
Generic Market Share Generic Product
Give Notice Holders Special Counsel Availability Shelf Registration Given Risks Uncertainties Not Place Undue Reliance Forward-looking
Global Securities General Goldman Sachs
Governing Law Jurisdiction Government Regulation
Governmental Authority Grants Plan-based Awards
Headings Headings Agreement Convenience Reference Only Shall Not Limit
Held 2005 Held Record Date Determining Stockholders Other Purpose Shall
Hiv Opportunity Hiv Portfolio
Hm74a Agonist Program Hm74a Type Diabetes
Hold Separate Transaction Holder Lists
Holders Obligations However
Hsd Program Hsd1 Program
Hsr Hsr Act
Http Wwwincytecom Human Resources
Iconix Pharmaceuticals Inc Ido Solid Tumors
Immediate Release Immunity Incorporators Stockholders Officers Directors
Implementing Objectives Incb-3284
Incb13739 Incb13739 Type Diabetes
Incb18424 Incb18424 Additional Myeloproliferative Diseases Polycythemia Vera Essential Thrombocythemia
Incb18424 Myelofibrosis Life-threatening Myeloproliferative Disease Incb18424 Other Oncology Indications
Incb18424 Psoriasis Topical Formulation Incb18424 Rheumatoid Arthritis
Incb19602 Type Diabetes Incb20817 Follow-on Compound
Incb28050 Incb28050 Follow-on Compound Inflammation
Incb28060 Incb3284 Oral Ccr2 Antagonist Inflammation-driven Diseases
Incb3284 Oral Ccr2 Antagonist Inflammation-driven Diseases Begin Phase Incb7839
Incb7839 Breast Cancer Incb7839 Oral Sheddase Inhibitor Cancer
Incb8696 Incb9471
Incentive Compensation Incentive Compensation Plan
Include Following Legend Securities Affiliate Security Include Following Legend Securities Restricted Other Affiliate
Include Global Security Income Taxes
Incorporation Reference Trust Indenture Act Increase Conversion Rate
Incur Additional Expense Order Market Drug Products Incyte
Incyte Announces 2005 Financial Results Incyte Announces 2005 Results
Incyte Announces Major Collaboration License Agreement Hematology-oncology Programs Incyte Compound
Incyte Compounds Incyte Confidential Information
Incyte Corporation Incyte Corporation Condensed Consolidated Balance Sheet Data
Incyte Corporation Condensed Consolidated Statements Comprehensive Loss Incyte Corporation Experimental Station Route 141 Henry Clay
Incyte Corporation Proxy Solicited Behalf Board Directors Annual Incyte Disclosure Notice
Incyte Investor Meeting Webcast Incyte Key Decision Points
Incyte Patent Rights Incyte Pool Compounds
Incyte Product Incyte Product Patent Rights
Incyte Program Patent Rights Incyte Receive 803 Payments Retains Rights Multiple Sclerosis
Incyte Receive Over Payments Including 150 Upfront Plus Incyte Received Sale Convertible Subordinated Pfizer Was
Incyte Registered Trademark Also Refer Trademarks Other Corporations Incyte Retains Co-development Co-promotion Options
Incyte Technology Incytes Approach Drug Discovery Development
Incytes Clinical Development Regulatory Team Incytes Development Teams
Incytes Retained Indications Ccr2 Compounds Incytes Transition Small-molecule Drug Discovery Development
Ind Indebtedness Debt Service Obligations
Indemnification Indemnification Contribution
Indemnifying Party Indenture
Independence Index
Indicate Check Registrant Well-known Seasoned Issuer Defined Rule Individual Rights Trustee
Inflammation Portfolio Information Requirements
Infringement Initial Purchaser
Initial Securities Intangible Assets
Intangible Other Assets Inter-company Sales
Interest Interest Expense
Interest Income Expense Interest Other Income Expense Net
Interest Other Income Net Internal Control-integrated Framework
Internal Software International Patent Protection Particularly Uncertain Costly Involved Opposition
Interpretation Patent Judgments Introduction
Investments Investments Decline Value Losses Increase
Investments Including Anticipated Expenditures Losses Expenses Invitrogen
Invitrogen Corporation Involved Patent Litigation Not Resolved Favorably Require Pay
Issue Description Execution Registration Exchange Securities Jak Inhibition
Jak Inhibitor Program Jak Inhibitor Programs Inflammation Oncology
Jak Program Inflammation Hematologic Malignancies Solid Tumors Jak Program Inflammatory Diseases Myeloproliferative Disorders Cancer
Janus Kinase Jak Inhibitor Program Janus-associated Kinase Jak Inhibitor Program
John Keller John Niblack Phd
Joint Research Committee Jrc
Jrc Functions Powers Julian Baker
Key Elements Executive Compensation Key Secondary Efficacy Endpoints
Large Amount Debt Service Obligations Prevent Taking Actions Launch
Laws Legal Proceedings
Legends Liabilities Connection Purchase Business Combination
License Pfizer License Royalty Revenues
Lilly Incyte Announce Collaboration Development Commercialization Oral Anti-inflammatory Limitation Incurrence Additional Indebtedness Certain Actions
Limitation Suits Limited Expertise Capacity Conduct Preclinical Testing Clinical Trials
Litigation Litigation Conditions
Lock-up Agreements Defined Hereof Accurate Complete Fair Long-term Investments
Long-term Investments Decline Value Losses Increase Long-term Investments Marketable Securities
Loss Certain Derivative Financial Instruments Net Loss Debt Repurchase
Losses Certain Derivative Financial Instruments Mail
Maintaining Escrow Account Maintenance Office Agency
Maintenance Properties Majority Voting Policy
Managements Annual Report Internal Control Over Financial Reporting Managements Discussion Analysis Financial Condition Results Operations
Manufacture Supply Market Registrants Common Equity Related Stockholder Matters
Market Registrants Common Equity Related Stockholder Matters Issuer Marketable Securities
Marketable Securities Subject Certain Risks Adversely Affect Overall Marketable Securities-available-for-sale
Material Modification Rights Security Holders Matthew Emmens
Maxia Acquisition Maxia Acquisition Costs
Meaning Other-than-temporary Impairment Application Certain Investments Meeting Take Action Authorized 801 Mailing Notice Thereof
Meetings Meetings Securityholders
Might Adversely Affected Might Not Able Commercialize Drug Candidates Successfully Spend
Milestone Payments Minutes
Miscellaneous Miscellaneous Provisions
Modification Extension Assumption Options Modified Myelofibrosis Symptom Assessment Form Mfsaf Diary
Mutual Termination Rights Myelofibrosis
Myeloproliferative Neoplasms Mpns Name Person Filing Proxy Statement Other Registrant
Named Executive Officers Nda
Need Additional Capital Future Markets Not Permit Raise Net Income Loss Per Share
Net Loss Net Loss Operating Expenses
Net Loss Per Share Net Sales
New Inflammation Program New Oncology Program
New Oncology Programs New Plan Benefits
New York Wilmington 2005 Nominating Corporate Governance Committee
Nominees Non-compete
Non-management Stock Option Committee Non-solicitation Employees
Nonstatutory Option Not Obtain Special Protocol Assessment Jak Inhibitor Myelofibrosis
Notation Exchange Securities Notice Annual Meeting Stockholders Held 2006
Notice Annual Meeting Stockholders Held 2007 Notice Default
Notice Holder Notice Holders Prior Certain Actions Case
Notice Questionnaire Notices
Notices Maintenance Restrictions Transfer Notwithstanding Replacement Trustee Pursuant Obligations 606 Shall Continue
Number 0-27488 Objectives Drug Discovery Development
Off Balance Sheet Arrangements Oncology Portfolio
Open Examination Stockholder Whole Time Meeting Reasonably Accessible Operating Expenses
Operating Results Opinion Limited Matters Governed General Corporation Law State
Option Option Grants Last
Optionee Shall Mean Individual Holds Option Organization Business
Other Business Agenda Other Compensation
Other Covenants Other Events
Other Expenses Other Income Expense
Other Programs Other Provisions
Outstanding Securities Overall Design
Overview Paragraph Notice
Pari Passu Part
Participant Shall Interest Voting Right Shares Covered His Participation
Participation Payroll Deductions Purchase Shares Particular Covenants
Parties Party
Party Claim Patent Rights
Patent Term Extension Patent Term Extensions
Patents Other Intellectual Property Patricia Schreck
Paul Brooke Paul Friedman
Paula Swain Paying Agent Hold Money Securities Trust
Payment Interest Payment Interest Conversion
Payment Method Payment Securities
Payment Shares Payment Taxes Other Claims
Payments Payment Reports Payroll Deductions
Perform Such Other Duties Powers Board Directors Chief Permissive Right Authority Granted Trustee Shall Not Construed
Person Person Annual Meeting
Persons Deemed Owners Pfizer
Pfizer Affiliates Shall Control Confidential Information Technology Process Pfizer Collaborative Research License Agreement
Pfizer Confidential Information Pfizer Development Reports
Pfizer Disclosure Notice Pfizer Indication
Pfizer Key Decision Points Pfizer Patent Claims
Pfizer Patent Rights Pfizer Process Patent Claims
Pfizer Product Pfizer Proprietary Process Patent Claims
Pfizer Technology Pharmasset Collaborative Licensing Agreement
Phase Trial Pipeline
Piper Jaffray Place Meetings Board Directors Hold Regular Special Either
Plan Plan Filing Stock Administrator Not Later Business Prior
Plan Shall Mean Employee Stock Purchase Pledge Assignment
Pledge Escrow Agreement Portal Market
Potential Payments Termination Connection Change Control Potential Payments Termination Without Change Control
Power Attorney Practical Accommodation Grant Date Defined Fasb Statement 123
Pre-approval Policies Procedures Preclinical Programs
Predecessor Security Preferential Collection Claims Against
Preferred Stock Price Approval
Pricing Primary Efficacy Endpoint
Principal Accountant Fees Services Principles Consolidation
Prior Occurrence Event Default After Curing Waiving Events Prior Restructurings
Prior Sale Such Registrable Securities Product Liability Indemnification
Product Liability Lawsuits Brought Against Face Substantial Liabilities Profitability Adequacy Capital Resources
Program Patent Rights Program Technology
Progress Most Advanced Drug Development Programs Properties
Property Equipment Proposal Amend Incyte Corporation 1991 Stock Plan
Proprietary Manufacturing Process Prospectus
Provide Such Holder Copies Documents Filed Pursuant Provided
Provided Further Provided However
Provision Benefit Income Taxes Provision Hereof Required Included Indenture Qualified Trust Act
Provision Income Taxes Proxies Solicited
Proxy Statement Proxy Statement Annual Report Available Http Bnymellonmobularnet Bnymellon
Proxy Statement Available Http Bnymellonmobularnet Bnymellon Incy Psoriasis Topical
Publications Publicity
Purchase Agreement Purchase Period Offering Shall Commence Enrollment Date End
Purchased In-process Research Development Purchased In-process Research Development Expenses
Quantitative Qualitative Disclosures Market Risk Ratification Independent Registered Public Accounting Firm
Recent Accomplishments Recent Accomplishments Drug Discovery Development
Recent Accomplishments Include Recent Accounting Pronouncements
Recent Developments Include Recent Developments Upcoming Plans Drug Discovery Development
Recent Progress Drug Development Programs Recitals
Reclassifications Recognition Liabilities Connection Purchase Business Combination
Recognition Other-than-temporary Impairment Planned Sale Security Whose Cost Record Holder
Records Records Audits
Refractory Prostate Cancer Multiple Myeloma Refrain Doing Connection Herewith Except Own Gross Negligence
Registrable Securities Registrants Telephone Number Including Area Code
Registrar Paying Agent Conversion Registration Expenses
Registration Filing Agreement Registration Procedures
Registration Rights Agreement Regulatory Affairs
Regulatory Approval Regulatory Authority
Regulatory Filing Related Party Disclosures
Related Party Transactions Reliance Other Parties Manufacture Drug Candidates Result Short
Remedies Trustee Securityholders Event Default Repayment
Replacement Securities Replacement Trustee
Report Audit Committee Board Directors Report Compensation Committee Board Directors Executive
Report Independent Registered Public Accounting Firm Reports
Reports Trustee Holders Representations Warranties Agreements
Representations Warranties Incyte Representatives
Repurchase Security Securityholder Elect Provided 1405 Required Vote
Research Costs Research Development
Research Development Costs Research Development Expenses
Research Licenses Research Plan
Resignation Removal Trustee Responsible Officer
Restoration Rights Remedies Restricted Stock Legend
Restrictions Transfer Beneficial Interest Global Security Certificated Restrictions Transfer Certificated Security Beneficial Interest Global
Restructuring Restructuring Charges
Restructuring Impairment Charges Restructuring Other Impairments
Restructuring Programs Results Businesses Investments
Results Operations Results Operations Financial Condition
Revenue Revenue Arrangements Multiple Deliverables
Revenue Recognition Revenues
Reverse Split Reverset Dexelvucitabine Dfc
Reverset Nucleoside-analogue Reverse Transcriptase Inhibitor Nrti Reverset Oral Nucleoside-analogue Reverse Transcriptase Inhibitor Nrti Phase
Reversion Notice Reverted Indication
Reverted Indications Revocation Effect Consents Waivers Actions
Rheumatoid Arthritis Richard Schutter
Right Convert Right Redeem
Rights Agreement Rights Duties Immunities Escrow Agent
Rights Remedies Cumulative Rights Trustee
Risk Adverse Safety Findings Risk Unanticipated Delays Research Development Efforts
Role Compensation Committee Chief Executive Officer Role Compensation Consultant
Roy Whitfield Royalty Payments
Royalty Term Expiration Date Rule 144
Rule 144a Rules Construction
Salary Sales Milestone Payments
Satisfaction Discharge Indenture Schedule
Schedule 103 Schedule 127
Schedule 128 Schedule 129
Schedule 130 Schedule 131
Schedule 132 Schedule 133
Schedule 134 Schedule 135
Schedule 14a Schedule 175
Schedule Convertible Subordinated Promissory Notes Issued Form 431 Schedule Convertible Subordinated Promissory Notes Issued Form 441
Schedule Ii-valuation Qualifying Accounts Scheduled End Following Calendar Unless Participant Elects Withdraw
Scheduled Interest Payments Sec Other Reports
Secured Obligations Securities
Securities Act Securities Issued Hereunder Fully Registered Form Make Appropriate
Securities Laws Securities Lieu Substitution Other Shall Been Authenticated Delivered
Securities Pursuant Shelf Registration Statement Giving Rise Such Securities Registered Pursuant Act
Securities Theretofore Canceled Trustee Delivered Cancellation Security Ownership Certain Beneficial Owners Management
Security Ownership Certain Beneficial Owners Management Related Stockholder Securityholder
Securityholders Securityholders Lists Reports Trustee
Seeking Impose Limitations Provisions Agreement License Segment Reporting
Selling General Administrative Expenses Series Participating Preferred Stock Purchase Rights
Service Service Shall Mean Member Board Directors Whether Not
Settlement Conversion Severability
Shall Mean Incyte Corporation Shall Mean Incyte Corporation Designated Subsidiary
Shall Mean Incyte Corporation Formerly Genomics Inc Delaware Share
Share-based Payment Shares Common Stock
Shares Purchased Participant Plan Shall Registered Name His Shares Then Entitled Vote Election Directors Unless Otherwise
Sheddase Inhibitor Sheddase Inhibitor Oncology
Sheddase Inhibitor Program Sheddase Inhibitor Program Solid Tumors
Shelf Registration Shelf Registration Statement
Signature Signatures
Significant Subsidiary Sources Uses Cash
Special Counsel Special Meeting 2009
Special Protocol Assessments Statement Pursuant Usc 1350
Stay Extension Usury Laws Stock
Stock Compensation Stock Compensation Plans
Stock Option Agreement Stock Option Awards
Stock Options Stock Plan
Stock Plan Amendment Stock Price Performance Graph
Stock Shall Mean Common 001 Par Value Stock Subject Plan
Stock-based Compensation Stockholder Proposals 2005 Annual Meeting
Stockholder Proposals 2007 Annual Meeting Stockholder Proposals 2008 Annual Meeting
Stockholder Record Stockholders Rights Plan
Study 203 Subject Additional Arbitration Litigation Infringement Claims They Costly
Subject Arbitration Litigation Infringement Claims They Costly Disrupt Sublicenses License Incyte
Submission Matters Vote Security Holders Subsequent Event
Subsidiaries Incyte Corporation Subsidiary
Substantial Part Property Such Involuntary Case Other Proceeding Successor Corporation
Successor Substituted Successor Trustee Merger
Summary Compensation Table Summary Results
Supplemental Indentures Table Contents
Table Contents Headings Tax Deductibility Compensation
Taxes Technology
Telephone Internet Temporary Securities
Term Term Options Subject Subsections Below Each Option Shall
Term Plan Amended Restated Shall Become Effective Date Termination Based Compensation Employment Agreements Offer Letters
Termination Connection Change Control Without Cause Good Reason Termination Employment
Termination Pfizer Termination Pfizer Indication
Termination Research Program Termination Security Interest
Termination Trading Termination Without Cause Good Reason Not Connection Change
Termination Without Good Reason Connection Change Control Termination Without Good Reason Prior Change Control
Terms Conditions Awards Sales Terms Conditions Options
Terms Options Terms Options Shares Offered Sale Restricted Stock Units
Test Compound Test Compounds
Testing Activities Incyte Third-party Beneficiaries
Tolerability Total Permanent Disability
Trademarks Transfer Exchange
Transfer Exchange Certificated Securities Transfer Global Security
Transfer Restrictions Set Forth Below Shall Apply Securities Transfer Securities
Transition Drug Discovery Transition Drug Discovery Development
Transition Plan Treatment Confidential Information
Trust Indenture Act Trustee
Trustee Enforce Claims Without Possession Securities Trustee Escrow Agent Perform
Trustee Holding Securities Shall Proved Registry Such Certificate Trustee Proofs Claim
Trustee Sign Supplemental Indentures Trustees Application Instructions
Trustees Disclaimer Unable Adequately Protect Enforce Proprietary Information Result Unauthorized
Unable Obtain Regulatory Approval Develop Market Products United Unconditional Right Holders Receive Principal Interest Convert
Underlying Common Stock Undertaking Costs
Unregistered Sales Equity Securities Update Drug Discovery Development Programs
Upfront Payment Usc 1350
Valid Claim Valuation Long-lived Assets
Vote Votes Counted
Voting Stock Waiver
Waiver Past Defaults Rescission Wall Street Journal
Wednesday 800am What Boards Recommendations
What Constitutes Quorum What Difference Between Holding Shares Stockholder Record Beneficial
What Householding Affect What Proposals Voted Annual Meeting
What Proposals Voted Special Meeting What Vote Required Approve Each
Wilmington Wilmington 2005
Wilmington 2007 Wilmington 2007-
Wilmington 2008 Wilmington 2009
Wilmington De-november 2008-incyte Corporation Wilmington Del 2006
Wilmington Del Business Wire 2009 Wilmington Del Feb 2006
Wilmington Del Feb 2007 Wilmington Del--november 2006
Wilmington Del-july 2006- Wire Transfer
Withdrawal Denial Regulatory Authoritys Approval Withdrawal Employee Stock Purchase Plan Termination Employment
Withholding Taxes Obligation Deliver Stock Exercise Option Shall Without Consent Holders
Witness Whereof Executed Subscribed Certificate Designation Affirm Foregoing Witness Whereof Parties Hereto Caused Indenture Duly Executed
Written Instructions Certificates Wwwincytecom
ßhsd1 Program Type Diabetes Related Disorders 
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki